{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-005981","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2022-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.988019+00:00","generated_at":"2026-06-26T05:20:28.901819+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Ultragenyx director Aliski to exit at 2022 annual meeting; appoints Amrit Ray to board","bullets":["William Aliski will not stand for re-election at 2022 annual meeting; departure for personal reasons, not disagreement.","Amrit Ray, M.D., appointed as Class III director effective April 19, 2022; also joins Research and Development Committee.","Ray is Chief Patient Officer at Biohaven (BHVN); previously senior roles at Pfizer and Johnson & Johnson.","Ray granted 5,120 RSUs and option for 9,525 shares at $78.10 exercise price under standard director compensation.","Board size set at ten directors: three Class I, three Class II, four Class III."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-005981","json":"https://secwatch.observer/filing/0000950170-22-005981.json","markdown":"https://secwatch.observer/filing/0000950170-22-005981.md","text":"https://secwatch.observer/filing/0000950170-22-005981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017022005981/0000950170-22-005981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017022005981/rare-20220418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:20:28.901819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"384306fda3","claim":"William Aliski departed as director at Ultragenyx Pharmaceutical Inc..","evidence_excerpt":"William Aliski notified Ultragenyx Pharmaceutical Inc. (the “ Company ”) that he will not stand for re-election as a member of the Board of Directors","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017022005981/0000950170-22-005981-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"not stand for re-election"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"48c7a88f36","claim":"Amrit Ray was appointed as Class III director at Ultragenyx Pharmaceutical Inc..","evidence_excerpt":"the Board appointed Amrit Ray, M.D. as a Class III director of the Board effective April 19, 2022","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1515673/000095017022005981/0000950170-22-005981-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}